Herbalife (HLF) investor relations material

Executive summary

• Q3 net sales rose 6.0% YoY to $1,350.2M, marking a fifth consecutive quarter of growth; adjusted EBITDA was $182.4M, and both exceeded guidance.

• Asia Pacific, led by India, drove growth; China and EMEA sales declined.

• Nine-month net income was $94.4M versus $142.9M, including a $94.6M debt-extinguishment loss; April refinancing lowered interest expense.

Financial highlights

• Q3 net sales were $1,350.2M versus $1,273.7M, up 6.0% reported and 7.6% local currency; volume rose 8.6%, pricing 2.8%, mix declined 3.8%, and FX reduced growth by 160 bps.

• Q3 operating income was $138.5M versus $125.8M; net income was $58.8M versus $43.2M, and diluted EPS was $0.55 versus $0.42.

• Adjusted net income was $68.5M and adjusted diluted EPS was $0.64; adjusted EPS included a $0.06 YoY FX headwind.

• Nine-month net sales increased 6.4% to $3,994.2M; net income was $94.4M versus $142.9M, with the comparison affected by the debt-extinguishment loss.

• Nine-month operating cash flow was $298.0M versus $235.0M; cash and cash equivalents were $409.2M at September 30, 2026.

Outlook and guidance

• Q4 reported net sales guidance is +0.5% to +4.5% YoY and constant-currency guidance is +2.5% to +6.5%; adjusted EBITDA guidance is $145M–$165M reported and $155M–$175M constant currency.

• FY26 reported sales growth guidance increased to +4.9% to +5.9% from +2.5% to +5.5%; constant-currency guidance is +5.3% to +6.3%.

• FY26 adjusted EBITDA guidance is $670M–$690M reported and $700M–$720M constant currency; constant-currency guidance increased from $690M–$710M.

• FY26 CapEx guidance is $55M–$65M; capitalized and prepaid SaaS costs are expected at $35M–$45M, D&A and SaaS amortization at $135M–$145M, and adjusted tax rate at ~35%.

• Technology Realignment Program is expected to deliver ~$15M in annual savings beginning in 2026, with ~$15M in total pre-tax costs and completion expected in 2026.